This webcast will review the current state of technology in gene therapeutics and examine trends in immuno-oncology and gene therapy for hematological malignancies.
- Immuno-Gene Therapeutics in Hematological Cancers: How Science Drives Study Strategy
- Tuesday, February 20, 2018
- 11:00 AM Eastern Standard Time
- 1 hour
- Ingredients for successful study planning and delivery
- Operationalizing studies to achieve conclusive data outcomes
- Data-driven approach to choosing the right sites in the right countries
- Key drivers to retaining patients and meeting study end points
- Exploring future trajectories in outsourcing models for innovative biotech companies
Executive Director, Oncology, Strategic Development, Premier Research
Luke Gill has an extensive scientific background and more than 20 years of drug development experience. Specializing in oncology, he has led numerous global CRO management teams and provided strategic assessment, management, and oversight of study enrollment and program metrics.
Prior to joining Premier Research in 2015, Mr. Gill was Director of Global Project Management for Hematology and Oncology at PPD, overseeing design and delivery of clinical development plans across multiple indications and specializing in early-phase oncology. He also served as Assistant Project Management Director at PPD, was CRO alliance program director for Merck Serono, and has held positions at Pfizer/Parke Davis, Astra, and Glaxo.
Mr. Gill holds a master’s degree in neuro and molecular pharmacology from the University of Bristol, a bachelor’s degree in biological sciences from the University of the West of England, and an MBA specializing in strategy and international enterprise from the Open University in the U.K.
Chief Medical Officer, Premier Research
Dr. Colin Hayward is Premier Research’s top medical expert, providing global leadership for patient safety, scientific and ethical governance, and delivery of exemplary customer service.
Possessing a rare combination of business and scientific expertise, Dr. Hayward entered the pharmaceutical world with a focus on anesthesia and intensive care after a career in hospital medicine. Using his expertise in local medical affairs and pharmacovigilance, Dr. Hayward became International Medical Leader at Roche, developing innovative medical marketing strategies for products in supportive care, anemia, and oncology.
In 2007 he joined the board of Prism Ideas Ltd. After helping grow Prism and earning a Queen’s Award for business, he came to Premier Research in 2012 as Vice President of Medical Affairs, providing round-the-clock medical support to ensure that customers’ multimillion-euro drug development projects met their goals and adhered to stringent safety rules. He left the company to serve as European Medical Director for Myriad Genetics and returned in 2015 to assume the newly created Chief Medical Officer position.
Dr. Hayward holds a degree in medicine from Guys and St. Thomas’s Hospitals, London.